Abass Alavi, Thomas J Werner, William Raynor, Poul Flemming Høilund-Carlsen, Mona-Elisabeth Revheim: Critical review of PET imaging for detection and characterization of the atherosclerotic plaques with emphasis on limitations of FDG-PET compared to NaF-PET in this setting. Am J Nucl Med Mol Imaging 2021;11(5):337-351. (Full Text, PDF)
Thaís B Minekawa, Allan O Santos, André G Moraes, André Sasse, Cleide A Silva, Marcelo T Lima, Mariana Camacho, Mariana C Lima, Elba Etchebehere: Single-center developing country analysis of radium-223 therapy in prostate cancer-preliminary results. Am J Nucl Med Mol Imaging 2021;11(5):352-362. (Full Text, PDF)
Rheal A Towner, Debra Saunders, Megan Lerner, Robert Silasi Mansat, Tian Yuan, Dylan Barber, Janet Faakye, Adam Nyul-Toth, Anna Csiszar, Beverley Greenwood-Van Meerveld, Nataliya Smith: Temporary opening of the blood-brain barrier with the nitrone compound OKN-007. Am J Nucl Med Mol Imaging 2021;11(5):363-373. (Full Text, PDF)
Cyrus Ayubcha, Grant Rigney, Austin J Borja, Thomas Werner, Abass Alavi: Tau-PET imaging as a molecular modality for Alzheimer’s disease. Am J Nucl Med Mol Imaging 2021;11(5):374-386. (Full Text, PDF)
Knut Håkon Hole, Andreas Julius Tulipan, Jeroen Sebastiaan Reijnen, Eivor Hernes, Ljiljana Vlatkovic, Agnes Kathrine Lie, Mona-Elisabeth Revheim, Therese Seierstad: Localization of primary prostate cancer: FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard. Am J Nucl Med Mol Imaging 2021;11(5):387-394. (Full Text, PDF)
Laura Saule, Maija Radzina, Mara Liepa, Lilita Roznere, Marika Kalnina, Andrejs Lioznovs, Edgars Mamis, Madara Mikelsone, Juergen Biederer, Egils Vjaters: Diagnostic scope of 18F-PSMA-1007 PET/CT: comparison with multiparametric MRI and bone scintigraphy for the assessment of early prostate cancer recurrence. Am J Nucl Med Mol Imaging 2021;11(5):395-405. (Full Text, PDF)
Charles Marcus, Olayinka A Abiodun-Ojo, Ashesh B Jani, David M Schuster: Clinical utility of 18F-Fluciclovine PET/CT in recurrent prostate cancer with very low (≤0.3 ng/mL) prostate-specific antigen levels. Am J Nucl Med Mol Imaging 2021;11(5):406-414. (Full Text, PDF)
Pegah Jahangiri, Alexandra D Dreyfuss, Fenghai Duan, Bradley S Snyder, Austin J Borja, Kamyar Pournazari, Esha Kothekar, Leila Arani, Abdullah Al-Zaghal, Siavash Mehdizadeh Seraj, Emily C Hancin, Benjamin Pinheiro, Thomas J Werner, Samuel Swisher-McClure, Steven J Feigenberg, Drew A Torigian, Mona-Elisabeth Revheim, Charles B Simone II, Abass Alavi: Implementation of FDG-PET/CT imaging methodology for quantification of inflammatory response in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Am J Nucl Med Mol Imaging 2021;11(5):415-427. (Full Text, PDF)
Ryan D Niederkohr, Stephen P Hayden, James J Hamill, Judson P Jones, Joshua D Schaefferkoetter, Edison Chiu: Reproducibility of FDG PET/CT image-based cancer staging and standardized uptake values with simulated reduction of injected FDG dose or acquisition time. Am J Nucl Med Mol Imaging 2021;11(5):428-442. (Full Text, PDF)
